Every material Form 8-K DAXOR CORP filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Daxor Corporation announced FDA 510(k) clearance (K251087) for its next-generation, rapid, portable lab-based Blood Volume Analyzer (BVA), according to a press release dated August 7, 2025. The filing does not include financial results or a financial impact estimate, so its effect on shareholders is not quantified.
FDA 510(k) clearance was granted under number K251087 for the new Daxor BVA device.
The company says the device provides results three times faster than its predecessor and weighs 7 lbs.
The system was developed under contract with the U.S. Department of Defense, including the U.S. Army and the Defense Health Agency.
The company states that more than 75,000 tests have shipped to date.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every DAXOR CORP filing is on SEC EDGAR ↗. 8-K briefs of other companies →